The bilateral initiative "Novel CARTs" funded by EEAGrants fundamentally supports the partnership between the group of Dr. Sébastien Wälchli of the Oslo University Hospital, specialist in the development of novel immunotherapeutic products such as chimeric antigen receptor (CAR), and the group of Dr. Celso Reis from the Institute of Research and Innovation in Health, holder of unique knowledge in glycoimmunology and glycobiology applied to cancer treatment.
The kick-off meeting of this initiative took place in 2020, where Portuguese and Norwegian researchers have discussed the topic of glycobiology applied to oncology and immunology.
The main objective of this bilateral cooperation is to characterize and evaluate the efficacy of novel therapeutic antibodies to treat cancer, through the application of the complementary know-how of the different members.
The next steps of this initiative involve a scientific working visit from Porto to Oslo to identify novel anti-glyco antibodies, the preparation of CAR molecules and their validation